Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct 23;310(16):1701-10.
doi: 10.1001/jama.2013.280034.

Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial

Lisa R Metsch  1 , Daniel J Feaster, Lauren Gooden, Bruce R Schackman, Tim Matheson, Moupali Das, Matthew R Golden, Shannon Huffaker, Louise F Haynes, Susan Tross, C Kevin Malotte, Antoine Douaihy, P Todd Korthuis, Wayne A Duffus, Sarah Henn, Robert Bolan, Susan S Philip, Jose G Castro, Pedro C Castellon, Gayle McLaughlin, Raul N Mandler, Bernard Branson, Grant N Colfax
Affiliations
Randomized Controlled Trial

Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial

Lisa R Metsch et al. JAMA. .

Abstract

Importance: To increase human immunodeficiency virus (HIV) testing rates, many institutions and jurisdictions have revised policies to make the testing process rapid, simple, and routine. A major issue for testing scale-up efforts is the effectiveness of HIV risk-reduction counseling, which has historically been an integral part of the HIV testing process.

Objective: To assess the effect of brief patient-centered risk-reduction counseling at the time of a rapid HIV test on the subsequent acquisition of sexually transmitted infections (STIs).

Design, setting, and participants: From April to December 2010, Project AWARE randomized 5012 patients from 9 sexually transmitted disease (STD) clinics in the United States to receive either brief patient-centered HIV risk-reduction counseling with a rapid HIV test or the rapid HIV test with information only. Participants were assessed for multiple STIs at both baseline and 6-month follow-up.

Interventions: Participants randomized to counseling received individual patient-centered risk-reduction counseling based on an evidence-based model. The core elements included a focus on the patient's specific HIV/STI risk behavior and negotiation of realistic and achievable risk-reduction steps. All participants received a rapid HIV test.

Main outcomes and measures: The prespecified outcome was a composite end point of cumulative incidence of any of the measured STIs over 6 months. All participants were tested for Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum (syphilis), herpes simplex virus 2, and HIV. Women were also tested for Trichomonas vaginalis.

Results: There was no significant difference in 6-month composite STI incidence by study group (adjusted risk ratio, 1.12; 95% CI, 0.94-1.33). There were 250 of 2039 incident cases (12.3%) in the counseling group and 226 of 2032 (11.1%) in the information-only group.

Conclusion and relevance: Risk-reduction counseling in conjunction with a rapid HIV test did not significantly affect STI acquisition among STD clinic patients, suggesting no added benefit from brief patient-centered risk-reduction counseling.

Trial registration: clinicaltrials.gov Identifier: NCT01154296.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. All authors, except Drs. Korthuis, Mandler, and Branson, report that their respective institution(s) received grant funds from the study sponsor for their effort on this study. Dr. Golden reports that his institution received grant funds from Cempra Pharmaceuticals, Gen-Probe, and Bio-Rad for his effort on work outside of this study. Ms. Haynes reports receiving support from the study sponsor (via a subcontract with the University of Miami) for travel to meetings for this study. Dr. Korthuis reports that his effort on this project was supported by a NIDA award, 1K23DA019809. Dr. Duffus reports that his institution received grant funds from Gilead for his effort on work outside of this study. Dr. Henn reports that her institution received grant funds from Gilead Sciences (GS-US-299-0102 and GS-US-3370102), GlaxoSmithKline (GSK ING114467), Pfizer (Wyeth6115A1-3017) and the NIH HIV Prevention Trials Network 065 (TLC-Plus) for her effort on work outside of this study. Dr. Bolan reports that his institution received support from the study sponsor for travel to meetings for this study; he receives funds from the Los Angeles Gay & Lesbian Center for his employment and Simply Speaking for lectures on HIV/AIDS; and his institution received grant funds from NIAID, NIDA, California AIDS Research Program, NIMCH/CHIPTS, and Ryan White parts A and C for his work outside of this study. No other disclosures were reported.

Figures

Figure 1
Figure 1
CONSORT FLOW DIAGRAM
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. HIV Surveillance Supplemental Report. 3 part A. Vol. 17. Centers for Disease Control and Prevention; [Accessed September 18, 2013]. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 US dependent areas: 2010. http://www.cdc.gov/hiv/library/reports/surveillance/2010/surveillance_Re....
    1. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PloS one. 2011;6(8) - PMC - PubMed
    1. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53(5):619–624. - PubMed
    1. Office of National AIDS Policy. [Accessed April 4, 2013.];National HIV/AIDS strategy for the United States. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf.
    1. Moyer VA on behalf of the U. S. Preventive Services Task Force. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(1):51–60. - PubMed

Publication types

Associated data